Form 4: Barinthus Biotherapeutics Executive Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


Leon Hooftman, Chief Medical Officer of Barinthus Biotherapeutics plc., reported multiple transactions in common stock on September 9, 2026.

Summary

  • Grant/award: acquired 361,530 Ordinary Shares on September 9, 2026; holds 361,530 after (Direct).
  • Disposition to the issuer: disposed of 361,530 Ordinary Shares on September 9, 2026 (Direct).
  • Disposition to the issuer: disposed of 195,166 Share Option (Right to Buy) on September 9, 2026 (Direct).
  • Disposition to the issuer: disposed of 140,000 Share Option (Right to Buy) on September 9, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Leon Hooftman — Officer (Chief Medical Officer)

DateTransactionSecuritySharesPriceValueHeld After
2026-09-09Grant/awardOrdinary Shares361,530——361,530
2026-09-09Disposition to the issuerOrdinary Shares361,530——0
2026-09-09Disposition to the issuerShare Option (Right to Buy)195,166——0
2026-09-09Disposition to the issuerShare Option (Right to Buy)140,000——0

Key Dates

DateDescription
2026-09-09Grant/award (361,530 shares)
2026-09-09Disposition to the issuer (361,530 shares)
2026-09-09Disposition to the issuer (195,166 shares)
2026-09-09Disposition to the issuer (140,000 shares)

Keywords

insider transaction, Form 4, BRNS, Barinthus Biotherapeutics plc., neutral, Leon Hooftman

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.